Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis

<div>OPLS-DA scores of plasma metabolic profiles in PC, DM, and normal groups, demonstrating the good fitness and predictive ability of the model in identifying the differential metabolite ions. <i>t</i>[<a href="/journals/ije/2021/9990768/#B1">1</a>]: the first predicted principal component; <i>t</i>[<a href="/journals/ije/2021/9990768/#B2">2</a>]: the first orthogonal principal component.</div>

International Journal of Endocrinology

fig3

Figure 3

Figure 3: Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis 